HLB (028300) Q1 2025 earnings summary

Executive summary

• Operates in three main segments: healthcare (diagnostics, medical devices), bio-pharmaceuticals (oncology drug development), and composite materials (marine/shipbuilding).

• Recent strategic focus on expanding bio and healthcare, including multiple acquisitions and R&D investments.

• Ongoing global clinical trials for key oncology drugs, with regulatory submissions in the US and Europe.

Financial highlights

• Q1 2025 consolidated revenue: KRW 17.66 billion, down from KRW 68.13 billion in FY2024.

• Q1 2025 operating loss: KRW -28.76 billion; net loss: KRW -68.92 billion.

• Cash and equivalents at Q1 2025: KRW 60.65 billion, down from KRW 93.05 billion at FY2024 year-end.

• Gross margin for Q1 2025: 26.7%.

• Basic EPS for Q1 2025: -490 KRW.

Outlook and guidance

• Focus on commercializing oncology drugs pending regulatory approval in the US and EU.

• Plans to expand global market presence for healthcare and diagnostic products.

• Continued investment in R&D and pipeline expansion, especially in bio-pharma.